Citadel Upgrades Questcor To Edge Positive, Raises PT To $44
Citadel Securities has upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Edge Positive and has raised the price target from $23 to $44.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: citadel securitiesUpgrades Price Target Analyst Ratings